×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Press Release

View printer-friendly version
Multimedia Available: FDA Approves Amgen's Neulasta for Serious & Frequent Chemotherapy Side Effect

Amgen (Nasdaq:AMGN) announced that the U.S. Food and Drug Administration has approved Neulasta(TM) (pegfilgrastim). Neulasta, administered as a single fixed dose per chemotherapy cycle, for decreasing the incidence of infection, as manifested by febrile neutropenia (fever associated with a severe drop in infection-fighting white blood cells) in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.

You can reach the story directly by going to http://www.newstream.com/cgi-bin/display_story.cgi?4945

This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics, and photos.

If you have any questions about the story, or about Newstream.com, please write to us at info@newstream.com.

--30--LS/na*

CONTACT: Newstream
info@newstream.com